New IDEAS Study Protocol
New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning Study
NCT04426539 (ClinicalTrials.gov)
 click schema graphic to enlarge |
New IDEAS is an observational, open-label, longitudinal cohort study designed to address the requirements of the CED provisions of the NCD on beta-amyloid PET. Building on the initial Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study, New IDEAS will evaluate the association between amyloid PET and patient-centered outcomes in an expanded and more ethnoracially and clinically diverse group of Medicare participants presenting with cognitive impairment. A total of 7,000 Medicare beneficiaries meeting the study’s eligibility criteria will be consented and enrolled over 30 months at sites throughout the United States. To ensure diversity, the study will enroll at least 2,000 Blacks/African Americans, at least 2,000 Latinos/Hispanics, and up to 3,000 additional participants from other racial and ethnic backgrounds. Based on disease stage prior to PET, all participants will be classified as having MCI or dementia. Based on their clinical presentation prior to PET, all participants will be classified as having “typical” (i.e., progressive amnestic) or “atypical” clinical presentations of AD.
Tailored recruitment strategies will be implemented to ensure inclusion of underrepresented populations including Black/African American patients, Latino/Hispanic patients, patients with early-onset (age < 65) cognitive impairment, and patients with typical or atypical presentation of MCI or dementia.
Dementia specialists will team with PET facilities that have trained radiologists/nuclear medicine physicians and access to perform amyloid PET. Amyloid PET will be performed and interpreted at each facility with results provided to the ordering physician for support in further decision making. The dementia specialists will record their diagnosis and intended management plan based on the current clinical and diagnostic information, and assuming no access to amyloid PET at the “pre-PET visit.” PET results will be disclosed to participants and changes in management will be recommended at the “PET disclosure visit.” Patients will return 90 ± 30 days following PET for an in-person “post-PET visit.” At this final visit, specialists will record the diagnosis and implemented management plan, incorporating amyloid PET into clinical decision making. Medicare claims data will be collected directly from CMS for 12 months prior to the PET imaging and 12 months after the PET imaging for each participant.
FAQ
What is New IDEAS?
What are the protocol differences between New IDEAS and the original IDEAS CED Study?
The New IDEAS study differs from the original study by:
- Sample size — New IDEAS has 7,000 (compared with approximately 18,000 in IDEAS, the largest Alzheimer’s disease study).
- Increased focus on recruitment of underrepresented minority populations.
- Includes early-onset and typical clinical presentations of Alzheimer’s disease.
- ApoE genotyping via saliva collection.
- Optional blood collection to establish a biorepository.
What are the patient enrollment timelines?
What is Coverage with Evidence Development (CED)?
The New IDEAS study is a CMS Coverage with Evidence Development (CED) study and is designed to be analogous to routine care.
Per cms.gov:
- CED is a paradigm whereby Medicare covers items and services on the condition that they are furnished in the context of approved clinical studies or with the collection of additional clinical data.
- A CED cycle is considered “completed” when CMS removes a requirement for study participation as a condition of coverage for one or more indications of an item or service.
The New IDEAS study will provide additional data to allow CMS to complete the CED cycle. This may result in Medicare coverage for a brain amyloid PET scan for all eligible Medicare beneficiaries. Once the CED cycle is complete, Medicare coverage, as in the New IDEAS Study, would continue to be subject to individuals’ benefits per their insurance plan(s).
For more information about CED see the CMS website.
Why is the New IDEAS Study important? What is at stake?
The New IDEAS study team will enroll 7,000 Medicare beneficiaries across the United States to kick off the study. Enrollment will include at least 2,000 Blacks/African Americans, at least 2,000 Latinos/Hispanics, and up to 3,000 additional participants from other racial and ethnic backgrounds to specifically address the dearth of racially and ethnically diverse research participants in Alzheimer’s disease clinical research.
Among the participants enrolled in New IDEAS, individuals with early-onset dementia (<65 years of age) will be included for analysis, as well as individuals of both typical or atypical clinical presentations of mild cognitive impairment and dementia. New IDEAS will also collect biological samples such as saliva and blood to be stored in a New IDEAS biorepository. New IDEAS researchers and others will use these samples to test and validate emerging genetic and plasma biomarkers for Alzheimer’s disease and all other dementia from an early and accurate diagnosis.
Finally, beyond amyloid PET, there are many additional biomarkers in development for Alzheimer’s disease and other causes of dementia. Results from the New IDEAS study will help create precedent and lay the groundwork for the type of information that regulators will need when considering coverage for future biomarkers.